Cargando…
Small-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse Chemotherapeutics
[Image: see text] Conventional chemotherapeutics remain essential treatments for most cancers, but their combination with other anticancer drugs (including targeted therapeutics) is often complicated by unpredictable synergies and multiplicative toxicities. As cytotoxic anticancer chemotherapeutics...
Autores principales: | Botham, Rachel C., Roth, Howard S., Book, Alison P., Roady, Patrick J., Fan, Timothy M., Hergenrother, Paul J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2016
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4999974/ https://www.ncbi.nlm.nih.gov/pubmed/27610416 http://dx.doi.org/10.1021/acscentsci.6b00165 |
Ejemplares similares
-
Dual Small-Molecule
Targeting of Procaspase-3
Dramatically Enhances Zymogen Activation and Anticancer Activity
por: Botham, Rachel C., et al.
Publicado: (2014) -
Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients
por: Joshi, Avadhut D., et al.
Publicado: (2017) -
Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain Cancers
por: Schlein, Lisa J., et al.
Publicado: (2019) -
Photofrin binds to procaspase-3 and mediates photodynamic treatment-triggered methionine oxidation and inactivation of procaspase-3
por: Hsieh, Y-J, et al.
Publicado: (2012) -
Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas
por: Holdhoff, Matthias, et al.
Publicado: (2023)